Clinical Trials Register

Trials with a EudraCT protocol (3,120)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

3,120 result(s) found for: Benign Tumor. Displaying page 1 of 156.

EudraCT Number: 2021-005919-30

Sponsor Protocol Number: AK_NEN_DOTA-FDG_21

Start Date*: 2022-09-21

Sponsor Name:Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet

Full Title: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms

Medical condition: Neuroendocrine neoplasms

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062476	Neuroendocrine tumor	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057270	Neuroendocrine carcinoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068916	Pancreatic neuroendocrine tumor metastatic	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071542	Neuroendocrine carcinoma metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10077560	Gastroenteropancreatic neuroendocrine tumor disease	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067518	Pancreatic neuroendocrine tumor	LLT
	24.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10085846	Duodenal neuroendocrine tumor	LLT
	24.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10085958	Small intestine neuroendocrine tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2008-005841-50

Sponsor Protocol Number: P08270471

Start Date*: 2008-11-17

Sponsor Name:Leids Universitair Medisch Centrum

Full Title: Adjuvant zoledronic acid in ‘high risk’ Giant Cell Tumour of bone (GCT) - A randomized phase II study -

Medical condition: high risk Giant Cell Tumour of bone

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10005970	Bone giant cell tumour benign	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-003936-21

Sponsor Protocol Number: TD-212-2308

Start Date*: 2015-09-14

Sponsor Name:Hôpital de Jolimont

Full Title: A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THE...

Medical condition: Progressive well or moderately differentiated neuroendocrine tumour of the pancreas

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067518	Pancreatic neuroendocrine tumor	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067517	Pancreatic neuroendocrine tumour	PT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068916	Pancreatic neuroendocrine tumor metastatic	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068909	Pancreatic neuroendocrine tumour metastatic	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: BE (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2012-002053-29

Sponsor Protocol Number: 03042012

Start Date*: 2012-08-10

Sponsor Name:Karolinska Institutet and University Hospital

Full Title: PET/CT-biopsi study A PET/CT biopsy sub study in patients who have given informed consent to participate in a randomized, dubbel blind, placebo controlled phase III trial with Capecitabine +/- So...

Medical condition: Morphological verifications of metastatic lesions, PET Ribonucleic Acid (RNA)-expression study in subjects with locally advance or metastatic HER2-negative breast cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10004244	Benign breast neoplasm NOS	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: SE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2008-004893-42

Sponsor Protocol Number: 1.0

Start Date*: 2008-10-15

Sponsor Name:Medizinische Universität Wien, Universitätsklinik für dermatologie

Full Title:

Medical condition: Condyloma accuminata, Vulvar Intraepithelial Neoplasia

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10047762	Vulval neoplasms benign	HLT
	9.1		10010291	Condyloma acuminatum	LLT

Population Age: Adults

Gender: Female

Trial protocol: AT (Completed)

Trial results: View results

EudraCT Number: 2020-005042-42

Sponsor Protocol Number: IASONFC303

Start Date*: 2021-06-27

Sponsor Name:IASON GmbH

Full Title: Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA ...

Medical condition: Prostate cancer suspected clinically and on the basis of elevated serum Prostate Specific Antigen (PSA) levels and/or PSA density and with result of multiparametric Magnetic Resonance Imaging (mpMR...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10060862	Prostate cancer	PT
	20.0	10022891 - Investigations	10053838	Free prostate-specific antigen increased	PT
	20.1	10022891 - Investigations	10050321	Prostate examination	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029096	Neoplasm prostate	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10004385	Benign neoplasm of prostate	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: AT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-000425-45

Sponsor Protocol Number:

Start Date*: 2012-07-03

Sponsor Name:

Full Title: Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.

Medical condition: Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067518	Pancreatic neuroendocrine tumor	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023400	Kidney cancer	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055008	Gastric sarcoma	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-005751-21

Sponsor Protocol Number: BLU-285-1408

Start Date*: 2021-04-16

Sponsor Name:Blueprint Medicines

Full Title: Open-Label Extension Study to Evaluate the Safety of Long-Term Treatment with Avapritinib for Patients Previously Involved in an Avapritinib Study

Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10051066	Gastrointestinal stromal tumour	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065252	Solid tumor	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029104	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	SOC

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: (No results available)

EudraCT Number: 2021-001403-33

Sponsor Protocol Number: TCTLR-101

Start Date*: 2023-06-06

Sponsor Name:Ascendis Pharma Oncology Division A/S

Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor...

Medical condition: Locally advanced or metastatic solid tumor malignancies

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10049280	Solid tumour	LLT
	21.1	100000004864	10065143	Malignant solid tumour	LLT
	21.1	100000004864	10065147	Malignant solid tumor	LLT
	21.1	100000004864	10065252	Solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2019-004052-11

Sponsor Protocol Number: UC-HNG/1909

Start Date*: 2020-07-08

Sponsor Name:UNICANCER

Full Title: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma

Medical condition: Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a di...

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041824	Squamous cell carcinoma of esophagus	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041859	Squamous cell carcinoma of the oral cavity stage 0	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041860	Squamous cell carcinoma of the oral cavity stage I	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041861	Squamous cell carcinoma of the oral cavity stage II	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041862	Squamous cell carcinoma of the oral cavity stage III	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041863	Squamous cell carcinoma of the oral cavity stage IV	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10031113	Oropharyngeal squamous cell carcinoma recurrent	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10031114	Oropharyngeal squamous cell carcinoma stage 0	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10031115	Oropharyngeal squamous cell carcinoma stage I	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021052	Hypopharyngeal squamous cell carcinoma recurrent	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021053	Hypopharyngeal squamous cell carcinoma stage 0	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021055	Hypopharyngeal squamous cell carcinoma stage II	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021054	Hypopharyngeal squamous cell carcinoma stage I	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041854	Squamous cell carcinoma of the hypopharynx stage III	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041853	Squamous cell carcinoma of the hypopharynx stage II	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041855	Squamous cell carcinoma of the hypopharynx stage IV	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023856	Laryngeal squamous cell carcinoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004395-34

Sponsor Protocol Number: C4221026

Start Date*: 2022-07-06

Sponsor Name:Pfizer Inc.

Full Title: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

Medical condition: solid tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10049280	Solid tumour	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065143	Malignant solid tumour	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065147	Malignant solid tumor	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065252	Solid tumor	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Ongoing) ES (Ongoing) IT (Ongoing) BE (Ongoing) SK (Ongoing) HU (Ongoing) CZ (Ongoing)

Trial results: (No results available)

EudraCT Number: 2014-000888-41

Sponsor Protocol Number: MetNET1trial

Start Date*: 2014-06-05

Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori

Full Title: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, mono...

Medical condition: advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor

Disease:	Version	SOC Term	Classification Code	Term	Level
	16.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067518	Pancreatic neuroendocrine tumor	LLT
	16.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068909	Pancreatic neuroendocrine tumour metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-001298-42

Sponsor Protocol Number: 1321

Start Date*: 2016-01-19

Sponsor Name:European Organisation for Research and Treatment of Cancer

Full Title: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Medical condition: unresectable metastatic GIST

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062427	Gastrointestinal stromal tumor	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10051066	Gastrointestinal stromal tumour	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029104	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	SOC

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Ongoing) ES (Ongoing) FI (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) DK (Prematurely Ended) IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-002360-14

Sponsor Protocol Number: AK-2016-HHC1

Start Date*: 2016-09-29

Sponsor Name:Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET

Full Title: Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer

Medical condition: Oral squamous cell cancer (OSCC) with and with out local metastasis Oropharyngeal squamous cell cancer (OPSCC) with and with out local metastasis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073040	Metastatic oropharyngeal cancer	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10030961	Oral cancer stage unspecified	LLT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10028801	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	HLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10031096	Oropharyngeal cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-000269-30

Sponsor Protocol Number: MO29518

Start Date*: 2015-08-26

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS

Medical condition: Patients with histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressed following at least one line of prior systemic anticancer therapy, or ...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062042	Lung neoplasm	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055108	Thymic cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10072737	Advanced breast cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039491	Sarcoma	PT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062878	Gastrooesophageal cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071114	Metastatic gastric adenocarcinoma	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10043670	Thymoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008593	Cholangiocarcinoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041823	Squamous cell carcinoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10004655	Biliary carcinoma	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061184	Germ cell cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10077559	Gastroenteropancreatic neuroendocrine tumour disease	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10049280	Solid tumour	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008229	Cervical cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061451	Colorectal cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066474	Thyroid cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061306	Nasopharyngeal cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006187	Breast cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10027412	Mesotheliomas	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) NL (Completed) IE (Completed) AT (Completed) ES (Completed) FI (Completed) GB (Completed) DK (Completed) PL (Completed) FR (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2014-004697-41

Sponsor Protocol Number: GO29664

Start Date*: 2015-08-19

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI−PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS

Medical condition: Pediatric solid tumors for which prior treatment has proven to be ineffective (i.e., relapsed or refractory) or intolerable

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029547	Non-Hodgkin's lymphoma	PT
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029260	Neuroblastoma	PT
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10047987	Wilms' tumor	LLT
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10020328	Hodgkin's lymphoma	LLT
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10031291	Osteosarcoma	PT
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039022	Rhabdomyosarcoma	PT
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075333	Soft tissue sarcoma	PT
	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015560	Ewing's sarcoma	PT

Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: DK (Completed) DE (Completed) IE (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2016-003102-14

Sponsor Protocol Number: IFG-NIB-01

Start Date*: 2017-09-19

Sponsor Name:Institut für Frauengesundheit GmbH

Full Title: A PHASE II ONE-ARM OPEN-LABEL NEOADJUVANT STUDY OF PEMBROLIZUMAB IN COMBINATION WITH NAB-PACLITAXEL FOLLOWED BY PEMBROLIZUMAB IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH TR...

Medical condition: Female patients with early, neoadjuvantly treated, triple negative breast cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021976	Inflammatory breast cancer stage IV	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071115	Node-negative breast cancer	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071113	Node-positive breast cancer	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021974	Inflammatory breast cancer	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021975	Inflammatory breast cancer stage III	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10063103	Tubular breast cancer stage I	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006194	Breast cancer NOS stage I	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10063104	Tubular breast cancer stage II	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006196	Breast cancer NOS stage III	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10063102	Tubular breast cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006195	Breast cancer NOS stage II	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006190	Breast cancer invasive NOS	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006192	Breast cancer NOS	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10063105	Tubular breast cancer stage III	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006199	Breast cancer stage I	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006200	Breast cancer stage II	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006201	Breast cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10054784	Contralateral breast cancer	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10021944	Infiltrating ductal breast cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073289	Premenopausal breast cancer	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057654	Breast cancer female	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10022882	Invasive ductal breast cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006283	Breast neoplasm malignant female	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075566	Triple negative breast cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006187	Breast cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2009-010918-30

Sponsor Protocol Number: 2377

Start Date*: 2009-08-11

Sponsor Name:Amar Agha, Beaumont Hospital

Full Title: Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.

Medical condition: 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been pr...

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10021067	Hypopituitarism	LLT
	9.1		10033662	Panhypopituitarism	LLT
	9.1		10056438	Growth hormone deficiency	LLT
	9.1		10011318	Craniopharyngioma	LLT
	9.1		10036832	Prolactinoma	LLT
	9.1		10011651	Cushing's disease	LLT
	9.1		10035104	Pituitary tumour	LLT
	9.1		10061538	Pituitary tumour benign	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: IE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2011-000240-16

Sponsor Protocol Number: 20110106

Start Date*: 2011-06-12

Sponsor Name:Skånes Onkologiska Klinik, Skåne University Hospital, Lund

Full Title: A MULTICENTER PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF 177Lu-DOTA-TATE BASED ON KIDNEY-DOSIMETRY IN PATIENTS WITH DISSEMINATED NEUROENDOCRINE TUMORS

Medical condition: Metastatic neuroendocrine tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10052399	Neuroendocrine tumour	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2014-000259-99

Sponsor Protocol Number: RG_13-277

Start Date*: 2014-08-29

Sponsor Name:University of Birmingham

Full Title: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

Medical condition: Recurrent and refractory Ewing sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015567	Ewing's tumor localized	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015763	Extra-osseous Ewing's sarcoma NOS	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015566	Ewing's tumor	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015762	Extra-osseous Ewing's sarcoma non-metastatic	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015761	Extra-osseous Ewing's sarcoma metastatic	PT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015569	Ewing's tumor recurrent	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015568	Ewing's tumor metastatic	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10058252	Ewing's tumour recurrent	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10058253	Ewing's tumour metastatic	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10058254	Ewing's tumour localised	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015564	Ewing's sarcoma recurrent	PT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015759	Extra-osseous Ewing's sarcoma	PT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015764	Extra-osseous Ewing's sarcoma recurrent	PT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015570	Ewing's tumour	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015562	Ewing's sarcoma metastatic	PT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015563	Ewing's sarcoma NOS	LLT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015560	Ewing's sarcoma	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FI (Ongoing) DE (Ongoing) HU (Ongoing) CZ (Ongoing) BE (Ongoing) NL (Ongoing) PL (Completed) IT (Temporarily Halted) AT (Ongoing)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Benign Tumor